Andrew J. Muratore

New York Biotechnology Association, Inc. promotes the biotechnology industry. It supports the development and growth of New York State''s life science industry, and serves its members and the life science community by providing a network for public policy, industry advocacy, and community development. The company is headquartered in New York, NY.

Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington.

MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom.

Reflexion Medical, Inc. develops medical devices. Its products include marketwired resonate and influencers, news distribution, IR and PR hosted newsroom and media database. The company was founded by Akshay Nanduri and Samuel Mazin in 2009 and is headquartered in Hayward, CA.

eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA.

Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom.

Penn State Research Foundation provides scientific research services aimed at improving human conditions. The non-profit company is based in University Park, PA.

Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel.

Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD.

Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA.

Lodo Therapeutics Corp. engages in the development of novel therapeutics from its metagenomics-based small molecule discovery platform. Its Lodo platform leverages breakthroughs in next-generation sequencing (NGS), artificial intelligence (AI), and machine learning (ML), along with advances in synthetic biology and automation. The company was founded by Sean Brady and David L. Pompliano and is headquartered in New York, NY.

Strata Oncology, Inc. manufactures oncology drugs. It provides comprehensive testing, portfolio of treatments, peace of mind. The company was founded by Daniel D. Rhodes, Scott Tomlin and Keith T. Flaherty in 2015 and is headquartered Ann Arbor, MI.

Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom.

ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX.

Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France.

Mitokinin, Inc. develops kinase neo-substrates for the treatment of neurodegenerative and mitochondrial diseases. The company was founded by Kevan Shokat, Nicholas Hertz, and Daniel de Roulet Jr. and is headquartered in New York, NY.

Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA.

Adapsyn Bioscience, Inc. operates as a biotechnology company focussed on the discovery and development of novel medicines. The company was founded by Nathan Magarvey and is headquartered in Hamilton, Canada.

Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom.

Magnolia Neurosciences Corp. operates as a drug discovery and development company. The firm focuses on the creation of a novel class of neuroprotective medicines. The company was founded in 2018 and is headquartered in Seattle, WA.

Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA.

Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA.

EvolveImmune Therapeutics Inc. engages in the provision of healthcare services. It offers immunotherapy platform to develop molecules for the treatment of oncology and immune diseases. The company was founded in 2019 and is headquartered in Westport, CT.

FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland.

Trex Bio, Inc. manufactures immunotherapies for autoimmune and inflammatory diseases. The company is headquartered in South San Francisco, CA.

Entrepreneurship Lab NYC is an entrepreneurship education and networking program that was founded in 2012. The program focuses on first-time founders with prior entrepreneurship education and is centered around bio and health tech. The goal of the program is to provide these founders with the basic skills and knowledge they need to succeed in their entrepreneurial endeavors.

Santi Therapeutics, Inc. provides pharmaceutical services. The company is headquartered in Boston, MA.

Montis Biosciences BV engages in the development of immune-oncology therapeutics targetting the intersection between vascular dysfunction and immune suppression to treat solid tumors. It offers target screening and assay platform to discover novel targets modulating interactions between tumor endothelial cells and perivascular macrophages. The company was founded by Peter Carmeliet and Massimiliano Mazzone and is headquartered in Meise, Belgium.

Kestrel Therapeutics, Inc. operates as a biotechnology development company. The company is based in Wayland, MA. The CEO of the company is Frank G. Haluska.

Incendia Therapeutics, Inc. develops a novel class of anti-cancer therapies. The company is based in Boston, MA. The company was founded in 2003 by Laurent Audoly, Colin Glenn Begley, Olga Granaturova, Guy Travis Clifton. Laurent Audoly has been the CEO since 2003.

Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022.